Critical Survey: GeoVax Labs (NASDAQ:GOVX) and Tango Therapeutics (NASDAQ:TNGX)

Tango Therapeutics (NASDAQ:TNGX) and GeoVax Labs (NASDAQ:GOVX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Tango Therapeutics and GeoVax Labs, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1	2	13	0	2.75
GeoVax Labs	1	1	1	0	2.00

Tango Therapeutics presently has a consensus target price of $43.46, indicating a potential upside of 77.76%. GeoVax Labs has a consensus target price of $150.00, indicating a potential upside of 46,454.93%. Given GeoVax Labs’ higher possible upside, analysts plainly believe GeoVax Labs is more favorable than Tango Therapeutics.

Risk & Volatility

Tango Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 3.69, suggesting that its stock price is 269% more volatile than the S&P 500.

Insider and Institutional Ownership

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by company insiders. Comparatively, 0.2% of GeoVax Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Tango Therapeutics and GeoVax Labs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
GeoVax Labs	N/A	-743.64%	-394.74%

Valuation & Earnings

This table compares Tango Therapeutics and GeoVax Labs”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38 million	66.09	-$101.59 million	($0.85)	-28.76
GeoVax Labs	$2.49 million	0.95	-$21.47 million	($11.34)	-0.03

GeoVax Labs has lower revenue, but higher earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Summary

Tango Therapeutics beats GeoVax Labs on 9 of the 13 factors compared between the two stocks.

About Tango Therapeutics

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

About GeoVax Labs

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.